Synergistic protective effect of paeoniflorin and β-ecdysterone against rotenone-induced neurotoxicity in PC12 cells

被引:0
作者
Han Liu
Chunlei Yu
Tianjiao Xu
Xiaojie Zhang
Miaoxian Dong
机构
[1] Qiqihar Medical University,The Institute of Medicine
来源
Apoptosis | 2016年 / 21卷
关键词
β-Ecdysterone; Paeoniflorin; Synergism; Parkinson’s disease; Apoptosis;
D O I
暂无
中图分类号
学科分类号
摘要
There are several factors, like oxidative stress and neurons loss, involving neurodegenerative diseases such as Parkinson’s disease (PD). The combination of antioxidant and anti-apoptotic agent is becoming a promising approach to fight against PD. This study evaluates the hypothesis that paeoniflorin (PF) and β-ecdysterone (β-Ecd) synergize to protect PC12 cells against toxicity induced by PD-related neurotoxin rotenone. The combination of PF and β-Ecd, hereafter referred to as the PF/β-Ecd, at suboptimal concentrations increased the viability of rotenone-exposed PC12 cells in a synergistic manner. PF and β-Ecd cooperate to attenuate the rotenone-induced apoptosis by decrease in Bax expression, caspase-9 activity, and caspase-3 activity. PF or PF/β-Ecd, but not β-Ecd, inhibited rotenone-triggered protein kinase C-δkinase C-δ (PKCδ) upregulation and nuclear factor κB (NF-κB) activation. β-Ecd or PF/β-Ecd, but not PF, enhanced serine/threonine protein kinase (Akt) activation, promoted nuclear factor E2-related factor 2 (Nrf2) nuclear accumulation, suppressed reactive oxygen species (ROS) production. Neuroprotection of PF/β-Ecd could be completely blocked by PKCδ inhibitor rottlerin plus Akt specific inhibitor LY294002. Dual blockade of the PKCδ/NF-κB pathway by PF and activation of Akt/Nrf2 pathway by β-Ecd results in a synergistic neuroprotective effect against rotenone-induced neurotoxicity in vitro. These findings provide the rationale for determining the in vivo activity of combined therapy with PF and β-Ecd against PD.
引用
收藏
页码:1354 / 1365
页数:11
相关论文
共 244 条
[1]  
Tahmasian M(2015)A systematic review on the applications of resting-state fMRI in Parkinson’s disease: does dopamine replacement therapy play a role? Cortex 73 80-105
[2]  
Bettray LM(2015)The phosphorylation of α-synuclein: development and implication for the mechanism and therapy of the Parkinson’s disease J Neurochem 135 4-18
[3]  
van Eimeren T(2014)Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson’s disease Mov Disord 29 1244-1251
[4]  
Drzezga A(2013)Implications of enzyme deficiencies on mitochondrial energy metabolism and reactive oxygen species formation of neurons involved in rotenone-induced Parkinson’s disease: a model-based analysis FEBS J 280 5080-5093
[5]  
Timmermann L(2015)Rotenone induction of hydrogen peroxide inhibits mTOR-mediated S6K1 and 4E-BP1/eIF4E pathways, leading to neuronal apoptosis Toxicol Sci 143 81-96
[6]  
Eickhoff CR(2015)Neuroprotective effects of Kukoamine B against hydrogen peroxide-induced apoptosis and potential mechanisms in SH-SY5Y cells Environ Toxicol Pharmacol 40 230-240
[7]  
Eickhoff SB(2015)Significance of antioxidant potential of plants and its relevance to therapeutic applications Int J Biol Sci 11 982-991
[8]  
Eggers C(2015)Plant-derived neuroprotective agents in Parkinson’s disease Am J Transl Res 7 1189-1202
[9]  
Xu Y(2014)Natural product-derived pharmacological modulators of Nrf2/ARE pathway for chronic diseases Nat Prod Rep 31 109-139
[10]  
Deng Y(2015)N-Propargyl caffeate amide (paca) potentiates nerve growth factor (NGF)-induced neurite outgrowth and attenuates 6-hydroxydopamine (6-OHDA)-induced toxicity by activating the Nrf2/HO-1 pathway ACS Chem Neurosci 6 1560-1569